Zevra Therapeutics, Inc. (ZVRA)
12.49
-0.05
(-0.40%)
USD |
NASDAQ |
Sep 04, 12:08
Zevra Therapeutics Cash from Investing (Quarterly) : 31.45M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.45M |
| March 31, 2026 | 79.62M |
| December 31, 2025 | 0.227M |
| September 30, 2025 | -4.576M |
| June 30, 2025 | 11.93M |
| March 31, 2025 | 10.54M |
| December 31, 2024 | -5.471M |
| September 30, 2024 | -31.35M |
| June 30, 2024 | -0.129M |
| March 31, 2024 | 14.79M |
| December 31, 2023 | 10.58M |
| September 30, 2023 | -44.46M |
| June 30, 2023 | 34.04M |
| March 31, 2023 | -17.56M |
| December 31, 2022 | -0.063M |
| September 30, 2022 | 0.272M |
| June 30, 2022 | -33.08M |
| March 31, 2022 | -3.848M |
| December 31, 2021 | -15.44M |
| September 30, 2021 | -0.004M |
| June 30, 2021 | -0.081M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | -0.026M |
| Date | Value |
|---|---|
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.004M |
| March 31, 2020 | -0.011M |
| December 31, 2019 | -0.005M |
| September 30, 2019 | -0.004M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 3.243M |
| December 31, 2018 | 7.964M |
| September 30, 2018 | 0.457M |
| June 30, 2018 | 15.68M |
| March 31, 2018 | 9.229M |
| December 31, 2017 | 10.02M |
| September 30, 2017 | 5.655M |
| June 30, 2017 | 6.039M |
| March 31, 2017 | 5.702M |
| December 31, 2016 | 5.739M |
| September 30, 2016 | 3.615M |
| June 30, 2016 | -40.47M |
| March 31, 2016 | -14.73M |
| December 31, 2015 | -19.04M |
| September 30, 2015 | -0.055M |
| June 30, 2015 | -0.019M |
| March 31, 2015 | -0.021M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Innoviva, Inc. | -55.26M |
| Collegium Pharmaceutical, Inc. | -502.59M |
| Johnson & Johnson | -1.11B |
| Ligand Pharmaceuticals, Inc. | 321.12M |
| Harrow, Inc. | -0.534M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 17.03M |
| Cash from Financing (Quarterly) | 1.585M |
| Free Cash Flow | 32.62M |
| Free Cash Flow Per Share (Quarterly) | 0.2741 |
| Free Cash Flow to Equity (Quarterly) | 16.47M |
| Free Cash Flow to Firm (Quarterly) | 16.82M |
| Free Cash Flow Yield | 4.40% |